SAFETY ANALYSIS OF PATIENTS TREATING WITH EGFR-TKIS AT A MEDICAL CENTER IN MIDDLE TAIWAN
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: ZHENG, Hong-Wen (Chung Shan Medical Universaty Hospital, Pharmacy, Taichung City, China Taiwan)
- Co-author(s): Hong-Wen Zheng
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been approved in the first-line therapy of EGFR mutation patients with non-small cell lung cancer by FDA. In our hospital, patients with EGFR mutation-positive lung cancer can be offered a therapeutic alternative of gefitinib, erlotinib and afatinib.
AEs reported due to.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.